ClinicalTrials.Veeva

Find clinical trials for Alzheimer's Disease in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Brain Diseases
Mental Disorders
Neurodegenerative Diseases
Nervous System Diseases

Alzheimer's Disease trials near Montréal, QC, CAN:

AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Montreal, Quebec, Canada and 111 other locations

be from 2 clinical subgroups: mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild Alzheimer's disease...

Active, not recruiting
Alzheimer's Disease
Drug: Lecanemab 2.5 mg/kg
Drug: Lecanemab 10 mg/kg

Phase 2

Eisai
Eisai

Montreal, Quebec, Canada and 168 other locations

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determin...

Active, not recruiting
Early Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Greenfield Park, Quebec, Canada and 246 other locations

administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's...

Enrolling
Alzheimer Disease
Drug: Placebo
Drug: ACU193

Phase 2, Phase 3

Acumen Pharmaceuticals

Greenfield Park, Quebec, Canada and 125 other locations

The aim of this study is to assess the efficacy and safety of GSK4527226 in participants with early Alzheimer's Disease (AD) (inclu...

Enrolling
Alzheimer's Disease
Other: Placebo
Drug: GSK4527226

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Greenfield-Park, Quebec, Canada and 103 other locations

study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's...

Enrolling
Alzheimer Disease, Early Onset
Other: Placebo
Drug: BMS-986446

Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Montreal, Quebec, Canada and 177 other locations

The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's...

Active, not recruiting
Alzheimer Disease
Cognitive Dysfunction
Drug: Placebo
Drug: JNJ-63733657

Phase 2

Janssen
Janssen

Montreal, Quebec, Canada and 122 other locations

In this study, researchers will learn more about a study drug called BIIB080. The study will focus on participants with mild cognitive impairment or...

Enrolling
Mild Cognitive Impairment Due to Alzheimer's Disease
Alzheimer's Disease Dementia
Drug: BIIB080
Drug: BIIB080-matching placebo

Phase 2

Biogen
Biogen

Montréal, Quebec, Canada and 130 other locations

as measured by changes in the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) score as compared with placebo in participants with early Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Drug: Aducanumab
Drug: Placebo

Phase 3

Biogen
Biogen

Greenfield-Park, Quebec, Canada and 210 other locations

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

Phase 3

Lilly
Lilly

Greenfield Park, Quebec, Canada and 275 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems